INVESTORS
NEWSROOM
Responsibility
SUBSCRIBE
CONSUMERS
HEALTHCARE PROFESSIONALS
CAREERS
ABOUT ABBOTT
Going From Strong to Stronger in 2021
Abbott President and CEO Robert Ford shared lessons from the pandemic and what's next at J.P. Morgan Healthcare.
Amidst a challenging 2020, Abbott remained strong and resilient thanks to the company's diversified portfolio of life-changing products.
As 2021 kicks-off, Abbott President and CEO Robert Ford participated in the virtual J.P. Morgan Healthcare Conference and shared what Abbott has learned from the pandemic, the future of COVID-19 testing and the company's growth opportunities in this new year.
"It was an incredibly unique period for us, but I'm proud of the way the company has risen to the challenge," Mr. Ford said. "It's why Abbott was built – for moments like these."
Lessons learned The pandemic reinforced the value of three key factors that helped highlight the company's resiliency in 2020, Mr. Ford told attendees at the conference:
Looking ahead Demand for Abbott's COVID-19 antigen and molecular tests is expected to remain high throughout 2021, Mr. Ford said. And as vaccinations increase, there likely will be an uptick in demand for Abbott’s antibody tests to assess the strength and duration of people's immune response. Longer term, demand for COVID-19 tests could transition to a steady state, similar to what's seen with the flu.
Beyond COVID-19 testing, Mr. Ford shared there's a lot going on at Abbott as the company continues creating the future of healthcare:
"We came into 2020 strong. I think we exited even stronger. I'm excited about the opportunities we have in front of us to not only have short-term returns, but also long-term sustainability for our business," Mr. Ford said.
For more information, listen to a replay of Mr. Ford's full conversation at the J.P. Morgan Healthcare Conference.
Please refer to www.freestylelibre.us for the indications and important safety information.
References
1 Data on File. Abbott Diabetes Care.